Home
Contact Us
About Us
Management Team
Board of Directors
Pipeline
MB-101
MB-102
Publications
Clinical Trials
Business Development
Investor Relations
Overview
Press Releases
SEC Filings
Events
Management Team
Board of Directors
Corporate Presentations
Corporate Governance
FAQ
Information Request
Email Notification
Pipeline
Product
Pre-clinical
Phase I
Phase II
MB-101 IL13Rα2-specific CAR
Glioblastoma
68%
MB-102 CD123 CAR
AML
63%
MB-103 HER2 CAR
Glioblastoma Multiforme
40%
MB-104 CS1 CAR
Multiple Myeloma
40%
MB-105 PSCA CAR
Prostate, Pancreatic, Gastric & Bladder Cancers
40%
MB-106 CD20 CAR
B-cell non-Hodgkin Lymphoma
63%